Bernstein analyst William Pickering maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.

Vertex Pharmaceuticals' estimated fair value is US$708 based on 2 Stage Free Cash Flow to Equity Vertex Pharmaceuticals is estimated to be 42% undervalued based on current share price of US$412 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...